Tvardi Therapeutics Announces Third Quarter 2026 Results and Provides Business Update

Tvardi's cash burn continues as clinical progress depends on new funding and regulatory clearance.

What the company is saying

Tvardi Therapeutics, Inc. (NASDAQ:TVRD) reports third quarter 2026 financials and updates on its clinical pipeline. The company highlights positive Phase 1 results for TTI-109 and plans to advance it into ulcerative colitis (UC) trials, but stresses that this is contingent on IND clearance and securing additional funding. CEO Imran Alibhai, Ph.D., frames the pipeline as making 'meaningful progress' and expresses confidence in both TTI-109 for UC and TTI-101 for hepatocellular carcinoma (HCC), with the next major milestone being topline data from the Phase 1b/2 HCC study expected in early Q1 2027. The announcement emphasizes pharmacodynamic evidence and preclinical data supporting STAT3 inhibition, but operational specifics are limited. Financial commentary explains that increased R&D expenses stem from higher clinical costs for TTI-101, while lower general and administrative expenses are attributed to reduced professional fees. The tone is measured but leans on forward-looking statements about future clinical milestones and the need for further capital.

What the data suggests

Research and development expenses rose to $4.5 million in Q3 2026 from $3.6 million in Q3 2025, driven by higher clinical costs for TTI-101. General and administrative expenses fell to $1.9 million from $2.3 million, reflecting lower professional fees. Net loss increased to $6.1 million from $5.5 million year-over-year, but net loss per share improved to $(0.48) from $(0.59) due to dilution or share count changes. Cash and cash equivalents dropped sharply from $30.8 million at year-end 2025 to $22.3 million as of September 30, 2026, indicating a significant cash burn. The company projects its current cash will fund operations into Q3 2027, but explicitly states that advancing TTI-109 into UC and other indications requires both IND clearance and new funding. While preclinical and Phase 1 data are referenced, no quantitative clinical or regulatory milestones have been achieved for TTI-109 in UC. The only near-term catalyst is topline data from the TTI-101 HCC trial, expected in early Q1 2027.

Analysis

The announcement provides a factual update on financials and pipeline status, with clear disclosure of R&D expenses, net loss, and cash position. However, most pipeline progress claims are forward-looking and contingent: advancement of TTI-109 into clinical trials is subject to both IND clearance and additional funding, and the next clinical milestone (TTI-101 HCC topline data) is not expected until early Q1 2027. While positive preclinical and Phase 1 data are referenced, no detailed numerical or operational results are disclosed for these studies, and there is no evidence of IND submission or trial readiness for TTI-109 in UC. The company is burning significant cash ($8.5M YTD) with declining reserves, and future progress is capital-dependent. The tone is measured, but the narrative emphasizes pipeline momentum and confidence despite the long execution timeline and funding risks.

Risk flags

• ●Pipeline advancement for TTI-109 in ulcerative colitis is explicitly contingent on both IND clearance and securing additional funding, creating material regulatory and financing risk. Without these, clinical progress cannot proceed.
• ●Cash and cash equivalents declined from $30.8 million at year-end 2025 to $22.3 million at September 30, 2026, reflecting a high cash burn rate. The company forecasts operational runway into Q3 2027, but this does not cover the costs of advancing new clinical programs.
• ●The announcement references positive preclinical and Phase 1 data but provides no detailed quantitative results or evidence of IND submission, enrollment, or trial readiness for TTI-109. This lack of operational detail increases uncertainty around actual pipeline progress.
• ●All major clinical milestones, including the initiation of TTI-109 trials and the TTI-101 HCC topline readout, are long-term and not imminent. Delays or setbacks in regulatory clearance, funding, or trial execution could push value realization further out.

Bottom line

Tvardi's Q3 2026 update shows rising R&D expenses ($4.5M), a growing net loss ($6.1M), and a shrinking cash position ($22.3M), with current funds projected to last into Q3 2027. Advancement of its lead asset TTI-109 in ulcerative colitis is on hold pending both IND clearance and new capital, making near-term progress uncertain. The only tangible upcoming catalyst is the topline readout from the TTI-101 HCC trial, expected in early Q1 2027, but all other pipeline milestones are long-dated and conditional. The company provides scientific rationale for its programs but little operational detail or evidence of regulatory momentum. Investors face clear execution and financing risks, and the story remains a long-term, high-risk proposition until new funding and regulatory progress are secured.

Announcement summary

(NASDAQ:TVRD) Tvardi Therapeutics, Inc. reported its financial and operating results for the third quarter ended September 30, 2026, and provided a business update. The company is advancing development plans for TTI-109 in ulcerative colitis (UC), building on positive Phase 1 healthy volunteer results reported in July and the subsequent selection of UC as its initial target indication. Tvardi is preparing to advance TTI-109 into clinical development in UC, subject to clearance of its Investigational New Drug (IND) application and additional funding. Phase 1 results confirmed the prodrug design, with TTI-109 delivering TTI-101-equivalent exposure with improved tolerability and demonstrated reductions in immune populations correlated with UC disease severity, providing pharmacodynamic evidence of STAT3 target engagement. Additional preclinical data published in the International Journal of Molecular Sciences showed that TTI-101 achieved colon tissue exposure approximately eightfold higher than in plasma, normalized disease-associated changes in colon gene expression, muted colitis-associated changes in the gut microbiome, and prevented the formation of colon adenocarcinomas in a preclinical model of chronic colitis. These findings build on prior preclinical studies in which TTI-101 and TTI-109 significantly reduced disease activity across three acute colitis models. The company is also advancing the Phase 1b/2 REVERT LIVER CANCER study evaluating TTI-101 as monotherapy and in combination with established therapies in patients with hepatocellular carcinoma (HCC), with topline data expected early in the first quarter of 2027. Key upcoming milestones include the initiation of a clinical trial of TTI-109 in UC in 2027, subject to IND clearance and additional funding, and the reporting of TTI-101 Phase 1b/2 HCC topline data in early first quarter of 2027. Research and development expenses for the three months ended September 30, 2026, were $4.5 million, compared to $3.6 million for the same period in 2025, primarily due to higher clinical costs associated with TTI-101. General and administrative expenses were $1.9 million for the three months ended September 30, 2026, compared to $2.3 million for the same period in 2025, primarily due to lower professional fees. Net loss for the three months ended September 30, 2026, was $6.1 million, compared to $5.5 million for the same period in 2025. Basic and diluted net loss per share attributable to common stockholders for the three months ended September 30, 2026, were both $(0.48), compared to $(0.59) for the same period in 2025. Cash and cash equivalents as of September 30, 2026, were $22.3 million, compared to $30.8 million as of December 31, 2025. Tvardi anticipates that its existing cash and cash equivalents will be sufficient to fund operations, as currently planned, into the third quarter of 2027. Advancing TTI-109 into UC and additional indications remains subject to additional funding and IND clearance. The company is conducting a Phase 1b/2 clinical trial of TTI-101 in hepatocellular carcinoma (NCT05440708). Imran Alibhai, Ph.D., Chief Executive Officer of Tvardi, commented on the progress across the pipeline and the company's confidence in TTI-109 and TTI-101.

Disagree with this article?